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Abstract
Objectives To describe NSAID utilization for musculoskeletal conditions in a large cohort of Italian elderly with cerebro/
cardiovascular disease, a population in which NSAIDs should be generally avoided due to the prothrombotic potential.
Methods Administrative data from five Italian geographic areas were analyzed. Patients aged ≥ 65 with a cerebro/cardiovascular
event recorded between 2008 and 2011 (cohort entry) were selected. Prescription NSAIDs reimbursed for musculoskeletal
conditions and dispensed during 1 year follow-up were retrieved to describe (i) prevalence of use, (ii) average amount of defined
daily doses of NSAIDs claimed by users per day of follow-up, and (iii) distribution of the received daily dose (RDD) among
patients with ≥ 2 dispensings. Among new users, i.e., patients without NSAID dispensings during 2 years before cohort entry, the
first dispensed NSAID molecule was observed.
Results Overall, 511,989 patients were selected. Across the five geographic areas, prevalence of use ranged from 48 to 21% and
average consumption ranged between 30 and 67 DDD/1000 users/day. Around 10% of patients in the overall cohort had a
RDD > 1. Nimesulide (9.6%) and diclofenac (7.5%) had the highest prevalence of use. The most consumed NSAIDs were
nimesulide and coxibs with 10.6 and 7.5 DDD/1000 users/day, respectively. Among new users recruited in 2011, 30% had
diclofenac or a coxibs as the first prescription.
Conclusions NSAID use was common in the study cohort, particularly in central-southern areas. In contrast with current
recommendations, coxibs and diclofenac were among the most prescribed active principles, even in new users. Interventions
to promote appropriateness of use are warranted.
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Introduction
Non-steroidal anti-inflammatory drugs (NSAIDs) are widely
used in clinical practice for the symptomatic treatment of
common medical conditions causing pain, fever, and inflam-
mation [1].
The analgesic, antipyretic, and anti-inflammatory effects of
NSAIDs are due to the inhibition of the cyclooxygenase
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enzyme (COX) which catalyzes the synthesis of prostanoids,
including thromboxane and prostaglandins, and mediates dif-
ferent biological effects [2].
Although all NSAIDs have comparable therapeutic effica-
cy, they may have different safety profiles in terms of gastro-
intestinal, cardiovascular, renal, or liver toxicity [3]. As con-
cerns the cardiovascular safety, all non-aspirin NSAIDs are
likely to increase the risk of adverse cardiovascular events,
though some specific active principles are considered more
hazardous than others [2–5]. Available NSAIDs are com-
monly distinguished in two main categories, Btraditional^
NSAIDs, generally regarded as non-selective with respect
to the inhibition of the two main isoforms of the cycloox-
ygenase enzyme COX-1/COX-2, and Bcoxibs^, which
show a pronounced selectivity towards COX-2 blockage.
Notably, although the hypothesis of COX-2 selectivity
explaining the NSAID-related prothrombotic risk has been
challenged and, by some, discarded [6], consolidated evi-
dence suggests that the use of coxibs, but also diclofenac, a
traditional NSAID with high selectivity for COX-2, can
significantly increase the risk of major cerebro/
cardiovascular (CCV) events, especially when used at high
doses and/or for long periods of treatment [2, 4, 5, 7]. A
recent meta-analysis of randomized trials reported a rela-
tive risk (RR) of 1.37, (95% confidence interval [CI] 1.14–
1.66) for coxibs and 1.41 (95%CI 1.12–1.78) for
diclofenac, versus placebo [4]. Comparable results were
also reported from a large meta-analysis of observational
studies [5]. Moreover, the latter study also showed that
baseline cardiovascular risk did not seem to modify the
relative risk of adverse cardiovascular events associated
to NSAID use compared to no use [4, 5, 8], although a
positive interaction in those with CCV diseases or with
older age (e.g., 80+) cannot be excluded [9, 10].
In Italy, over 20 different NSAID molecules are currently
on the market [11] and can be purchased either with or without
medical prescription depending on the specific active sub-
stance, formulation, and indication of use. In particular, the
Italian National Healthcare Service (NHS) limits the reim-
bursement of NSAID-containing medicines to some formula-
tion for systemic use, only when prescribed for specific indi-
cations, mostly musculoskeletal conditions (i.e., arthropathies,
osteoarthritis, gout) [12].
Current recommendations for the use of NSAIDs for the
symptomatic treatment of musculoskeletal indications in pa-
tients at high cardiovascular risk [2] limit the administration of
these medicines to those cases in which other pharmacother-
apies (e.g., paracetamol with/without weak opioids) resulted
ineffective. The lowest effective dose for the shortest duration
should be used. Moreover, among available active principles,
naproxen should be regarded as the safest NSAID in this pop-
ulation, while the use of coxibs or diclofenac is strongly dis-
couraged [2, 4, 5].
Given the wide spread use of NSAIDs, serious cardiovas-
cular events due to possible inappropriate utilization behaviors
might become a public health issue, particularly in those pop-
ulations with high baseline risk [1, 4, 7]. With this respect,
elderly patients represent a population in which CCV diseases
and severe musculoskeletal conditions frequently coexist [13,
14], so that NSAID use is likely to remain in many cases
necessary in spite of general contraindications.
In this context, evidence from drug utilization studies be-
comes fundamental to identify possible signals of irrational
uses, discuss measures and interventions to improve prescrib-
ing habits, and estimate the magnitude of potential safety is-
sues [15]. However, little is currently known on the real-world
patterns of utilization of NSAIDs in such a special population
[2, 14, 16].
Therefore, the aim of this study was to describe the pattern
of utilization of prescription NSAIDs reimbursed for the treat-
ment of musculoskeletal conditions in a large cohort of elderly
patients with CCV disease from five Italian geographic areas.
Materials and methods
Source of data
Italy has a tax-based, universal coverage Italian National
Healthcare Service (NHS) organized in three levels: national,
regional, and local. Local Health Authorities (LHA) are re-
sponsible for managing healthcare services delivered to all
subjects registered with a general practitioner in the corre-
sponding geographic areas, while the monitoring and promo-
tion of the appropriate use of healthcare resources, including
the issue of drug safety advisories to prescribers and pharma-
cists, can be planned and implemented either at national, re-
gional, or local level.
The utilization of healthcare services reimbursed by the
NHS is recorded in administrative databases which allow
linking patients’ demographics to records of prescription
drugs dispensed to outpatients, as well as to hospital discharge
records. Records of drug dispensing for outpatient use include
information on the dispensed medicine (active substance,
Anatomical Therapeutic Chemical-ATC code [17], brand
name, formulation), the number of boxes, and the date of
dispensing, though the indication of use for which the drug
is prescribed is not recorded. Hospital discharge records pro-
vide information on diagnoses and medical procedures, coded
with ICD9CM terminology, as well as the dates relevant to
each hospitalization event.
The data used for the present study were retrieved from the
administrative databases of five health authorities participat-
ing to the I-GrADE project (Italian Group for Appropriate
Drug Prescription in the Elderly) that was funded by the
Italian Medicines Agency. The databases collect information
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from five Italian geographic areas, corresponding to three re-
gions, Lazio (Center), Toscana (Center), and Lombardia
(North), and two Local Health Authorities, Caserta (South)
and Treviso (North). The catchment area of these databases
covers about 20 million inhabitants, corresponding to over
30% of the Italian population [18].
Cohort selection and study design
This was a multi-database, descriptive, population-based, ret-
rospective cohort study. Administrative data collected in the
five above mentioned geographic areas between 2008 and
2012 were used. All patients with a hospital diagnosis of
CCV disease (Appendix 1 - electronic supplementary materi-
al) recorded between January 1, 2008 and December 31, 2011
were selected (cohort entry), except for the Lazio region
where the latest date of cohort entry was June 30, 2010 due
to limited data availability. Patients younger than 65 years at
cohort entry or with less than 2 years of look-back period were
excluded. Moreover, patients diagnosed with cancer at any
time prior to the entry date were excluded.
All patients in the study cohort were followed-up for 1 year
after cohort entry or until the occurrence of one of the follow-
ing events, whichever came first: acute CCVevent (Appendix
2 - electronic supplementary material), cancer, death, end of
the study period (December 31, 2012).
For each patient in the cohort, all reimbursed dispensings
of systemic NSAIDs (ATC code: M01A*) recorded up to
1 year after cohort entry were retrieved and analyzed.
Although indication of drug use is not usually recorded in
the administrative data sources used for this study, systemic
NSAID-containingmedicines can be reimbursed by the Italian
NHS if prescribed for the treatment of musculoskeletal condi-
tions (i.e., arthropathies, osteoarthritis, gout) and neoplasm-
related pain [12]. Therefore, by excluding cancer patients
from the study cohort, we reasonably assumed that the ob-
served NSAID dispensings were actually used for the treat-
ment of musculoskeletal conditions.
Statistical analysis
The characteristics of the selected patients, both in the overall
study population and per geographic area, were described in
terms of age, gender, comorbidities, and concomitant pharma-
cotherapies (Appendixes 3 and 4 - electronic supplementary
material). Continuous variables were described as mean
values; categorical variables as percentages.
Trends of the prevalence of use (percentage of patients with
≥ 1 dispensings during 1 year after cohort entry) and average
daily consumption among prevalent users were observed per
year of cohort entry, geographic area, and specific NSAID
molecule. The average daily NSAID consumption was
measured using the defined daily dose (DDD) [17] and
expressed as DDD/1000users/day.
To identify patients that were possibly exposed to high
daily doses of NSAIDs (i.e., more than 1 DDD per day) [2],
the distribution of the received daily dose (RDD) was inves-
tigated among patients with ≥ 2 dispensings of any NSAID
during follow-up [19]. Although the actual patient usage of
drugs cannot be determined using electronic databases, the
RDD provides an approximation of patients’ daily exposure
to NSAIDs based on the amount of drug actually claimed by
patients between the first and last observed NSAID dispens-
ing. Therefore, the RDD was calculated by applying the fol-
lowing formula: [total DDD between first and last dispensing
observed during follow-up]/[days of follow-up between first
and last dispensing + the duration of the last dispensing],
where the duration of the last dispensing was equal to the
number of dispensed DDD.
We also investigated the percentage of new users, i.e., pa-
tients without any NSAID dispensing during the 2 years pre-
ceding cohort entry and with 1 or more NSAID prescriptions
during follow-up.Within this sub-population, also the average
daily consumption was described. Moreover, new users were
classified on the basis of the first active substances dispensed
after cohort entry, and the percentage of new users per active
substance and year of cohort entry was reported.
All the analyses were performed using the statistical soft-
ware STATA, version 13.1.
Results
The overall study population comprised 511,989 elderly pa-
tients with CCV disease. Patients’ characteristics at cohort
entry are reported in Table S1 (available in the electronic sup-
plementary material).
Prevalence of NSAID use per geographic area ranged from
20.8% in Treviso to 47.8% in Caserta (Table 1). The preva-
lence of NSAID use per year in the total study population
decreased from 30.7% in 2008 to 23.3% in 2011, with a sim-
ilar trend of decrease in all the geographic areas considered,
except for Lazio. In the overall study cohort, the highest prev-
alence of use per active substance was observed for
nimesulide (9.6%) and diclofenac (7.5%), while 3.8% of pa-
tients received at least one dispensing of a coxib and 0.7%
received naproxen.
The average daily consumption among prevalent users
ranged from 29.9 DDD/1000users/day in Treviso to 67.1
DDD/1000 users/day in Lazio (Table 2). The highest con-
sumption in the total study cohort per active substance was
observed for nimesulide and coxibs (10.6 and 7.5 DDD/1000
users/day, respectively) followed by diclofenac (7.2 DDD/
1000 users/day). The average daily consumption of naproxen
among NSAID users was 1.3 DDD/1000 users/day. Between
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Table 1 Prevalence of use of
NSAIDs during the first year of
observation, according to
geographic area
Caserta Lazio Toscana Lombardia Treviso Total
Patients, N 19.610 84.351 130.664 265.221 12.163 511.989
Prevalence of use (crude), % 47.8 41.8 29.7 22.8 20.8 28.6
Prevalence of use (age-sex
standardized), %
46.6 41.7 30.2 22.7 21.1 28.6
Prevalence of use (age-sex standardized) by year of cohort entry, %
2008 48.7 41.7 31.6 24.4 22.6 30.7
2009 48.1 41.9 30.6 23.0 21.6 29.8
2010 44.7 41.2 29.7 22.2 20.6 27.5
2011 42.5 28.1 19.8 18.2 23.3
Prevalence of use (crude) by active substance, %1
Nimesulide 20.0 17.9 10.0 6.4 3.1 9.6
Diclofenac 13.4 9.7 10.1 5.1 4.0 7.5
Ketoprofen 16.8 10.8 3.9 3.6 3.2 5.4
Ibuprofen 4.8 5.8 5.8 4.9 6.2 5.3
Coxibs2 7.3 7.1 3.1 2.8 3.7 3.8
Ketorolac 6.5 4.4 2.3 1.4 1.9 2.4
Piroxicam 3.7 2.3 1.7 1.7 1.3 1.9
Aceclofenac 2.6 1.8 1.0 1.2 1.2 1.3
Meloxicam 2.0 1.3 1.0 0.6 0.5 0.9
Naproxen 1.3 1.1 0.6 0.6 0.3 0.7
1Active substances with values lower than those observed for Naproxen were not reported
2 The category coxibs contains both celecoxib and etoricoxib
Table 2 Amount of NSAIDs
dispensed to prevalent users
during the first year of follow-up,
according to geographic area
Caserta Lazio Toscana Lombardia Treviso Total
Prevalent users, N 9365 35,268 38,900 60,513 2534 146,580
DDD/1000 users/day (crude) 47.7 67.1 37.3 39.9 29.9 44.4
DDD/1000 users/day (age-sex standard-
ized)
47.5 67.1 37.2 39.8 29.9 44.3
DDD/1000 users/day (age-sex standardized) by year of cohort entry
2008 36.9 54.3 27.9 30.9 27.9 35.6
2009 46.1 75.8 34.9 37.0 26.8 44.7
2010 55.0 117.0 44.8 50.7 34.3 55.8
2011 97.2 – 73 80.7 40.8 77.2
DDD/1000 users/day (crude), by active substance1
Nimesulide 12.3 18.7 9.8 8.1 2.6 10.6
Coxibs2 7.3 13.2 4.7 6.9 7.6 7.5
Diclofenac 6.7 8.2 7.8 6.5 4.9 7.2
Ketoprofen 9.6 10.2 2.9 3.9 3.2 5.2
Ibuprofen 2.3 4.8 5.0 5.6 5.3 5.1
Piroxicam 1.8 2.3 1.4 1.8 1.1 1.8
Aceclofenac 1.6 1.8 0.9 1.7 1.4 1.5
Meloxicam 1.6 1.8 1.3 1.3 0.9 1.4
Naproxen 1.2 1.9 0.9 1.5 0.6 1.3
1Active substances with values lower than those observed for naproxen were not reported
2 The category coxibs contains both celecoxib and etoricoxib
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2008 and 2011, the NSAID consumption in the study cohort
increased from 35.6 to 77.2 DDD/1000 users/day, consistently
across the five geographic areas.
Around 10% of prevalent users with at least two dispens-
ings during follow-up had a RDD > 1 (Fig. 1). No major dif-
ferences with respect to the distribution of the RDD were
observed across years of cohort entry or geographic areas
(data not shown).
New users accounted for 6.2% of the overall study cohort
(Table S2 - electronic supplementary material). The average
daily consumption was 23.7 DDD/1000 users/day (Table S3 -
electronic supplementary material). In each year of the study
period, around 2% of new users received naproxen as the first
dispensed molecule (Fig. 2). Coxibs were dispensed in around
8% of new users that entered the study in 2008 and in 9% of
those recruited during 2011. The percentage of patients who
received diclofenac as the first dispensed NSAID ranged be-
tween 18% among new users recruited in 2008 and 21% in
2011.
Discussion
Results from this study provided evidence on the real-world
utilization of NSAIDs for musculoskeletal conditions in a
large cohort of elderly with CCV disease from five Italian
geographic areas. Overall, the prevalence of use was about
30%, although a remarkable variability across the different
areas considered was observed. Average daily NSAID con-
sumption among prevalent users was also inconsistent across
geographical areas. In particular, the observed values of these
twomeasures of drug utilization were about two-fold higher in
Caserta and Lazio (central-South Italy) compared to
Lombardia and Treviso (North). Such variability observed is
unlikely to be completely explained by the known higher ten-
dency to the private drug purchasing in northern Italian re-
gions [20] and/or by the underlying differences in frequency
of musculoskeletal conditions (prevalence of arthritis/
osteoarthritis estimated from national survey data is 13.6%
in Lombardia and 18% in Campania) [13]. Rather, these find-
ings might reflect an excessive and inappropriate use of
NSAIDs in patients at high CCV risk in the areas of central
and South Italy compared to the North.
Overall trends of NSAID utilization during the study peri-
od showed a decrease of the prevalence of use over time, with
a concomitant increase of the average daily consumption per
NSAID user. Probably, the increasing awareness on the poten-
tial CCV toxicity of NSAIDs led clinicians to avoid prescrib-
ing these medicines to those patients for whom NSAID use
was not strictly necessary and for which safer alternatives
were available [2].
The distribution of the RDD showed that most of NSAID
users with ≥ 2 dispensings during follow-up were treated with
low doses and/or for short treatment periods. However, one
out of ten patients were possibly exposed to high doses of
NSAID (i.e., > 1 DDD per day of treatment).
The utilization of the specific active substances observed in
the present study cohort showed a clear disagreement with
current knowledge and recommendations on NSAIDs use
[2, 4, 5, 21]. Nimesulide, a traditional NSAID with a high
selectivity for the COX-2 [2, 22], was by far the most pre-
scribed active principle even though available evidence on
cardiovascular safety cannot be considered conclusive [3,
23–25]. Notably, due to concerns on liver toxicity, the indica-
tions of use of nimesulide have been progressively restricted:
in 2007, treatment duration was limited to a maximum of
Fig. 1 Distribution of the
received daily dose among
patients with at least two NSAIDs
dispensings during follow-up.
RDD received daily dose
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15 days; in 2010, the drug was no longer indicated as first-line
pharmacotherapy; and, finally, in 2012, nimesulide use was
further restricted to the symptomatic treatment of acute pain,
excluding painful osteoarthritis [26]. As a consequence of
such regulatory interventions, a slight decrease of the prescrip-
tion of nimesulide in new NSAID users was observed.
Diclofenac and coxibs were among the most prescribed
NSAIDs, following nimesulide. On the basis of consolidated
evidence, these active substances are currently contraindicated
in patients with, or at high risk for, cardiovascular disease [2,
7, 27]. Conversely, naproxen that is considered the safest
NSAID in this population [2, 4, 5] was strongly underutilized.
Notably, as for coxibs, regulatory actions were already under-
taken in 2005 to limit their use in patients at risk for CCV
events [27]. However, no impact on the prescription pattern of
coxib-containing medicines was observed in the present study
cohort of elderly patients with CCV disease. The utilization of
selective COX-2 inhibitors was high, even among new users,
and the percentage of those receiving a coxib as the first
NSAID dispensing did not change during the study period.
The main strength of this study is represented by the large
scale of the study cohort. Moreover, to the best of our knowl-
edge, this is the first study focusing on NSAID utilization for
musculoskeletal conditions in a large cohort of elderly patients
with CCV disease. The possibility of comparing NSAID uti-
lization across different geographical areas of the Italian terri-
tory represents a further strength of this study, since it facili-
tated the contextualization and critical discussion of findings.
As concerns study limitations, first, the actual NSAID expo-
sure in the study cohort might have been slightly
underestimated since non-reimbursed NSAIDs, including
both prescription and over-the-counter formulations, are not
captured in the data source used for this study. Nevertheless,
exposure misclassification in the present cohort is likely to be
minor since elderly patients have frequent encounters with
physicians, and NSAIDs are fully reimbursed when pre-
scribed for the treatment of musculoskeletal conditions.
Second, the indication of the use of the reimbursed NSAID
dispensings observed in this study was not validated.
However, among all the observed NSAID dispensings, only
few injectable formulations could be reimbursed regardless of
indication, though those approved for other conditions (e.g.,
postoperative pain), accounted for less than 10% of all ob-
served dispensings in our study cohort.
In conclusion, results of this study showed that NSAIDs are
commonly prescribed for the treatment of musculoskeletal
conditions in elderly patients with CCV disease. Comparing
the observed patterns of utilization across different geographic
areas and with current recommendations on NSAID use, our
findings highlighted some inappropriate prescribing behaviors
that should be addressed in order to promote a safer use of
these medicines. With this respect, a possible overutilization
was observed in the central-southern geographic areas con-
cerned. In particular, an extensive prescription of nimesulide,
coxibs, and diclofenac was highlighted, even in new NSAID
users. Considering the widespread use of NSAIDs worldwide,
CCVevents potentially attributable to the inappropriate use of
these drugs should be considered a public health issue.
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